Cognitive Go/No-Go decision-making criteria in Alzheimer’s disease drug development
Go/No-Go decision making in early phase clinical trials is challenging for drug developers working in Alzheimer’s disease. Recent negative trial results have been attributed to a lack of efficacy and important safety concerns. Furthermore, demonstrated target […]
